Pulmonary hypertension (PH) is a complex and progressive condition characterized by elevated pressures in the pulmonary arteries. Understanding its pathophysiology, diagnosis, and management is crucial for healthcare professionals.
PH originates from diverse etiologies leading to remodeling of the pulmonary vasculature, resulting in increased pulmonary vascular resistance and pulmonary arterial pressure. This ultimately causes right ventricular hypertrophy and heart failure.
Diagnosis of PH can be challenging due to its nonspecific symptoms. Initial diagnosis involves echocardiography, followed by right heart catheterization for confirmation. Additionally, various other tests like pulmonary function tests, chest radiography, and computed tomography can aid in identifying the underlying causes.
PH is classified into five groups based on etiology: Pulmonary arterial hypertension (PAH), PH due to left heart disease, PH due to lung diseases and/or hypoxia, Chronic thromboembolic PH (CTEPH), and PH with unclear multifactorial mechanisms. Each group requires a different treatment approach.
Treatment of PH is multifaceted and depends on the underlying cause. General measures include oxygen therapy, diuretics, and anticoagulation. Specific therapies for PAH include endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogues. In cases of CTEPH, pulmonary endarterectomy or balloon pulmonary angioplasty may be considered.
The prognosis of PH is generally poor, with survival rates varying greatly depending on the underlying cause. However, early diagnosis and appropriate management can significantly improve patient outcomes.
As healthcare professionals, it is essential to understand the complexities of PH to ensure accurate diagnosis and effective treatment. Continued research and advancements in targeted therapies hold promise for improved prognosis and quality of life for patients with PH.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation